Guaifenesin 400mg
NDC 10135-682
Product Information
Guaifenesin 400mg is a OTC MONOGRAPH DRUG-approved product labeled by Marlex Pharmaceuticals Inc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a white product. This product entry covers the primary NDC 10135-682 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
G400
Code Structure Chart
Product Details
What is NDC 10135-682?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- GUAIFENESIN (UNII: 495W7451VQ)
- GUAIFENESIN (UNII: 495W7451VQ) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- FD&C RED NO. 40 (UNII: WZB9127XOA)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MALTODEXTRIN (UNII: 7CVR7L4A2D)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- POVIDONE (UNII: FZ989GH94E)
- STEARIC ACID (UNII: 4ELV7Z65AP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 359601 - guaiFENesin 400 MG Oral Tablet
- RxCUI: 359601 - guaifenesin 400 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.
Patient Education
Guaifenesin
Guaifenesin is used to relieve chest congestion. Guaifenesin may help control symptoms but does not treat the cause of symptoms or speed recovery. Guaifenesin is in a class of medications called expectorants. It works by thinning the mucus in the air passages to make it easier to cough up the mucus and clear the airways.
[Learn More]
* Please review the full disclaimer at the bottom of this page.